Michael Edward Szperka

Array ( [id] => 20129443 [patent_doc_number] => 12371747 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy [patent_app_type] => utility [patent_app_number] => 17/681435 [patent_app_country] => US [patent_app_date] => 2022-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 114 [patent_no_of_words] => 53313 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17681435 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792066 [patent_doc_number] => 20220251157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => IgM-MEDIATED RECEPTOR CLUSTERING AND CELL MODULATION [patent_app_type] => utility [patent_app_number] => 17/674438 [patent_app_country] => US [patent_app_date] => 2022-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16196 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17674438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17828476 [patent_doc_number] => 20220265780 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => FACTOR VIII-FC CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/587941 [patent_app_country] => US [patent_app_date] => 2022-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24769 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17587941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17749667 [patent_doc_number] => 20220227871 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => ANTI-PD-L1 ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/579517 [patent_app_country] => US [patent_app_date] => 2022-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19446 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17579517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17704639 [patent_doc_number] => 20220204645 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => ANTIBODIES THAT RECOGNIZE RED BLOOD CELL ANTIGENS [patent_app_type] => utility [patent_app_number] => 17/571075 [patent_app_country] => US [patent_app_date] => 2022-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13776 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17571075 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034202 [patent_doc_number] => 20240084017 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => MONOCLONAL ANTIBODY AGAINST HUMAN MAC-1 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/259958 [patent_app_country] => US [patent_app_date] => 2021-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6722 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18259958 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17761534 [patent_doc_number] => 20220235146 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => ANTI-IgE ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/541932 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41212 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17541932 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17460339 [patent_doc_number] => 20220073644 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => BISPECIFIC ANTIBODY EXHIBITING INCREASED ALTERNATIVE FVIII-COFACTOR-FUNCTION ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/528371 [patent_app_country] => US [patent_app_date] => 2021-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24918 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17528371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18212457 [patent_doc_number] => 20230058721 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => Procoagulant Antibodies [patent_app_type] => utility [patent_app_number] => 17/522949 [patent_app_country] => US [patent_app_date] => 2021-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56494 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17522949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17837752 [patent_doc_number] => 20220275057 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => FACTOR VIII CHIMERIC PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/519719 [patent_app_country] => US [patent_app_date] => 2021-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57344 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17519719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18893818 [patent_doc_number] => 20240009303 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => COMBINATION VACCINE FOR PROTECTING SWINE AGAINST VARIOUS DISORDERS [patent_app_type] => utility [patent_app_number] => 18/250106 [patent_app_country] => US [patent_app_date] => 2021-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6388 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895495 [patent_doc_number] => 20240010980 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => NATURAL KILLER CELLS WITH ENHANCED ACTIVITY [patent_app_type] => utility [patent_app_number] => 18/249991 [patent_app_country] => US [patent_app_date] => 2021-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17454 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18249991 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17587727 [patent_doc_number] => 11325983 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-10 [patent_title] => Bispecific antibodies [patent_app_type] => utility [patent_app_number] => 17/501548 [patent_app_country] => US [patent_app_date] => 2021-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31201 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17501548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17356842 [patent_doc_number] => 20220017638 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => METHOD OF TREATING ATHEROSCLEROSIS [patent_app_type] => utility [patent_app_number] => 17/498112 [patent_app_country] => US [patent_app_date] => 2021-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24361 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17498112 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482274 [patent_doc_number] => 20220089778 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => COAGULATION FACTOR BINDING PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/450423 [patent_app_country] => US [patent_app_date] => 2021-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33214 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17450423 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18786121 [patent_doc_number] => 20230374128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => THERAPEUTIC AGENT FOR IMMUNE/INFLAMMATORY DISEASE [patent_app_type] => utility [patent_app_number] => 18/030901 [patent_app_country] => US [patent_app_date] => 2021-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14956 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18030901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19242045 [patent_doc_number] => 12012464 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-18 [patent_title] => Factor XI antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 17/450122 [patent_app_country] => US [patent_app_date] => 2021-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 45889 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 401 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17450122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18770902 [patent_doc_number] => 20230365706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => NOVEL ANTI-GLYCAN ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/030368 [patent_app_country] => US [patent_app_date] => 2021-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20419 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18030368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18844510 [patent_doc_number] => 20230406914 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => METHODS FOR REDUCING HOST CELL PROTEIN CONTENT IN ANTIBODY PURIFICATION PROCESSES AND ANTIBODY COMPOSITIONS HAVING REDUCED HOST CELL PROTEIN CONTENT [patent_app_type] => utility [patent_app_number] => 18/247198 [patent_app_country] => US [patent_app_date] => 2021-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24013 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18247198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18753983 [patent_doc_number] => 20230357340 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => Recombinant Fusion Proteins Comprising Interleukin-18-Binding Protein and Antigen Binding Fragment to Serum Albumin, and Compositions and Uses Thereof [patent_app_type] => utility [patent_app_number] => 18/246423 [patent_app_country] => US [patent_app_date] => 2021-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27440 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246423 [rel_patent_id] =>[rel_patent_doc_number] =>)